IYH and XBI: Two Distinct Paths to Investing in Healthcare

The State Street SPDR S&P Biotech ETF posted a higher 1-year total return than the broad iShares U.S. Healthcare ETF, but its maximum drawdown was significantly deeper at 53.2%. The comparison highlights the biotech fund's greater downside volatility; no return figures or broader market reaction were provided.

Analysis

The comparison is better read as a risk-budget choice than a clean performance signal. Biotech’s higher trailing return alongside a 53.2% maximum drawdown points to substantially greater path risk; it does not establish that biotech has better forward returns or that the drawdown has ended. In a risk-off tape, biotech volatility can prompt de-risking and ETF outflows, potentially amplifying weakness in smaller, less-liquid holdings. Broad healthcare may offer more diversified exposure across business models, but the article provides no holdings, valuation, or return-period detail to quantify that cushion.

Near term, rates, risk appetite, and fund flows are likely to matter more for biotech than for diversified healthcare. Over 1–3 months, verify relative flows, breadth of biotech performance, and whether gains are concentrated in a few names. Over 6–18 months, clinical and regulatory outcomes remain important idiosyncratic drivers; ETF diversification cannot eliminate trial or approval gaps. The contrarian point is that a large historical drawdown can make biotech look automatically unattractive, while a stronger trailing return can make it look safer than it is. Neither metric alone supports a directional call.

Key Decisions for Investors

• Do not chase biotech solely on its higher trailing return. Treat the 53.2% drawdown as evidence of meaningful downside and path risk, not as a valuation signal.
• For a healthcare allocation where drawdown control is the priority, favor the broader iShares U.S. Healthcare ETF over the State Street SPDR S&P Biotech ETF; size biotech as a higher-volatility satellite only if that risk is intentional.
• No standalone long/short trade is warranted from these data. Before considering a relative-value position, check current holdings overlap, valuation, flows, and comparable return windows.
• Reassess if biotech’s relative strength broadens and persists alongside improving flows; reduce the risk thesis if relative weakness deepens or volatility rises. A broad risk-off move or rate repricing could reverse either ETF’s near-term trend.